Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders

PurposeWe analyzed the Exome Aggregation Consortium (ExAC) data set for the presence of individuals with pathogenic genotypes implicated in Mendelian pediatric disorders.MethodsClinVar likely/pathogenic variants supported by at least one peer-reviewed publication were assessed within the ExAC database to identify individuals expected to exhibit a childhood disorder based on concordance with disease inheritance modes: heterozygous (for dominant), homozygous (for recessive) or hemizygous (for X-linked recessive conditions). Variants from 924 genes reported to cause Mendelian childhood disorders were considered.ResultsWe identified ExAC individuals with candidate pathogenic genotypes for 190 previously published likely/pathogenic variants in 128 genes. After curation, we determined that 113 of the variants have sufficient support for pathogenicity and identified 1,717 ExAC individuals (~2.8% of the ExAC population) with corresponding possible/disease-associated genotypes implicated in rare Mendelian disorders, ranging from mild (e.g., due to SCN2A deficiency) to severe pediatric conditions (e.g., due to FGFR1 deficiency).ConclusionLarge-scale sequencing projects and data aggregation consortia provide unprecedented opportunities to determine the prevalence of pathogenic genotypes in unselected populations. This knowledge is crucial for understanding the penetrance of disease-associated variants, phenotypic variability, somatic mosaicism, as well as published literature curation for variant classification procedures and predicted clinical outcomes.

[1]  A. Baruchel,et al.  Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia , 2010, Journal of Medical Genetics.

[2]  K. Boycott,et al.  Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.

[3]  C. Tyler-Smith,et al.  Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. , 2012, American journal of human genetics.

[4]  J. Ioannidis,et al.  Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates. , 2016, JAMA.

[5]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[6]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[7]  H. Ida,et al.  Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry , 2015, American journal of hematology.

[8]  Ryan W. Kim,et al.  Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing , 2011, Science Translational Medicine.

[9]  Brian T. Naughton,et al.  Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases , 2016, Nature Biotechnology.

[10]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[11]  J. Svendsen,et al.  Integration of 60,000 exomes and ACMG guidelines question the role of Catecholaminergic Polymorphic Ventricular Tachycardia‐associated variants , 2017, Clinical genetics.

[12]  Andrea Superti-Furga,et al.  Exome Sequencing and the Management of Neurometabolic Disorders. , 2016, The New England journal of medicine.

[13]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[14]  L. Vissers,et al.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome , 2011, Nature Genetics.

[15]  R. Płoski,et al.  M34T and V37I mutations in GJB2 associated hearing impairment: Evidence for pathogenicity and reduced penetrance , 2007, American journal of medical genetics. Part A.

[16]  I. Screpanti,et al.  Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. , 2010, American journal of human genetics.

[17]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[18]  Bo Yuan,et al.  Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. , 2001, American journal of human genetics.

[19]  L. Vissers,et al.  Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome. , 2012, American journal of human genetics.

[20]  M. Loh,et al.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.

[21]  Glenn A. Maston,et al.  A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders , 2015, Human mutation.

[22]  M. Hurles,et al.  Clinical delineation of the PACS1‐related syndrome—Report on 19 patients , 2016, American journal of medical genetics. Part A.

[23]  Peter Szolovits,et al.  Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.

[24]  G. Rivard,et al.  Gaucher disease: Variability in phenotype among siblings , 2004, Journal of Inherited Metabolic Disease.

[25]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[26]  J. Casanova,et al.  Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies , 2014, The Journal of experimental medicine.

[27]  R. Green,et al.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans , 2016, Science Translational Medicine.

[28]  Claire Redin,et al.  XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. , 2013, American journal of human genetics.

[29]  Paul Shannon,et al.  VariantAnnotation: a Bioconductor package for exploration and annotation of genetic variants , 2014, Bioinform..

[30]  G. Scarano,et al.  Two novel patients with Bohring–Opitz syndrome caused by de novo ASXL1 mutations , 2012, American journal of medical genetics. Part A.

[31]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[32]  Beryl B. Cummings,et al.  Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring–Opitz Syndrome , 2017, Human mutation.

[33]  C. Mason,et al.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo , 2013, The Journal of experimental medicine.

[34]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[35]  G. Bejerano,et al.  Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers , 2016, Genetics in Medicine.

[36]  Gonçalo R. Abecasis,et al.  The variant call format and VCFtools , 2011, Bioinform..

[37]  S. Letovsky,et al.  Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification , 2015, Genetics in Medicine.

[38]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.